Adicet Bio, Inc. Logo

Adicet Bio, Inc.

Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.

ACET | US

Overview

Corporate Details

ISIN(s):
US0070021086
LEI:
Country:
United States of America
Address:
131 DARTMOUTH STREET, 2116 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Adicet Bio, Inc. is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies. The company is advancing a pipeline of first-in-class, 'off-the-shelf' T cell product candidates for the treatment of cancer and autoimmune diseases. Adicet's proprietary platform leverages the unique properties of gamma delta T cells to engineer therapies with novel targeting mechanisms and the potential for best-in-class drug exposure. These treatments are designed to be readily available 'on-demand,' aiming to establish a new generation of immune cell therapy for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Adicet Bio, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Adicet Bio, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Adicet Bio, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

PURPLE BIOTECH LTD. Logo
Develops first-in-class therapies targeting tumor immune evasion and drug resistance in cancer.
United States of America
PPBT
Pyxis Oncology, Inc. Logo
Developing next-gen ADC and Immuno-Oncology therapeutics for difficult-to-treat cancers.
United States of America
PYXS
PZ Cormay S.A. Logo
Manufactures and distributes IVD reagents and analyzers for human and veterinary medicine.
Poland
CRM
Q32 Bio Inc. Logo
Clinical-stage biotech developing biologic therapies for autoimmune and inflammatory diseases.
United States of America
QTTB
Quantum Biopharma Ltd. Logo
Develops therapies for brain disorders and a functional beverage for post-alcohol wellness.
United States of America
QNTM
Quantum Genomics Logo
Biopharma developing cardiovascular treatments, now in judicial liquidation.
France
ALQGC
QuidelOrtho Corp Logo
Manufactures in-vitro diagnostic tests for at-home, point-of-care, and clinical lab settings.
United States of America
QDEL
Quince Therapeutics, Inc. Logo
Late-stage biotech developing red blood cell-encapsulated drugs for rare diseases.
United States of America
QNCX
Quoin Pharmaceuticals, Ltd. Logo
Clinical-stage pharma developing therapies for rare and orphan diseases like Netherton Syndrome.
United States of America
QNRX
Quratis Inc. Logo
Develops infectious disease vaccines and offers biologics CDMO services for global health.
South Korea
348080

Talk to a Data Expert

Have a question? We'll get back to you promptly.